{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:46:40Z","timestamp":1790063200212,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["17-75-30035"],"award-info":[{"award-number":["17-75-30035"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Ministry of Solidarity and Health, Assistance-Publique Hopitaux de Paris, Sorbonne Universite, Inserm and CardioMetabolism and Nutrition University Hospital Institute, France","award":["ANR-10-IAHU"],"award-info":[{"award-number":["ANR-10-IAHU"]}]},{"name":"French Ministry of Solidarity and Health, Assitance-Publique Hopiteaux de Paris, Sorbonne Universit\u00e9, Inserm and CardioMetabolism and Nutrition University Hospital Institute France","award":["ANR-10-IAHU"],"award-info":[{"award-number":["ANR-10-IAHU"]}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 107064"],"award-info":[{"award-number":["WT 107064"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC Metabolic Disease Unit","award":["MRC-MC-UU_12012\/2"],"award-info":[{"award-number":["MRC-MC-UU_12012\/2"]}]},{"name":"Instituto de Salud Carlos III and the European Regional Development Fund","award":["PI18\/01890"],"award-info":[{"award-number":["PI18\/01890"]}]},{"name":"Conselleria de Industria, Xunta de Galicia","award":["ED341b 2017\/19"],"award-info":[{"award-number":["ED341b 2017\/19"]}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrilena","doi-asserted-by":"crossref","award":["Call 2015"],"award-info":[{"award-number":["Call 2015"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015621","name":"UCIBIO","doi-asserted-by":"crossref","award":["UID\/MULTI\/04378\/2019"],"award-info":[{"award-number":["UID\/MULTI\/04378\/2019"]}],"id":[{"id":"10.13039\/501100015621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state. Because of the rarity of each lipodystrophy subform, research in this area is difficult and international co-operation mandatory. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for patients with lipodystrophy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The registry was build using the information technology Open Source Registry System for Rare Diseases in the EU (OSSE), an open-source software and toolbox. Lipodystrophy specific data forms were developed based on current knowledge of typical signs and symptoms of lipodystrophy. The platform complies with the new General Data Protection Regulation (EU) 2016\/679 by ensuring patient pseudonymization, informational separation of powers, secure data storage and security of communication, user authentication, person specific access to data, and recording of access granted to any data. Inclusion criteria are all patients with any form of lipodystrophy (with the exception of HIV-associated lipodystrophy). So far 246 patients from nine centres (Amsterdam, Bologna, Izmir, Leipzig, M\u00fcnster, Moscow, Pisa, Santiago de Compostela, Ulm) have been recruited. With the help from the six centres on the brink of recruitment (Cambridge, Lille, Nicosia, Paris, Porto, Rome) this number is expected to double within the next one or 2 years.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A European registry for all patients with lipodystrophy will provide a platform for improved research in the area of lipodystrophy. All physicians from Europe and neighbouring countries caring for patients with lipodystrophy are invited to participate in the ECLip Registry.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Study registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> (NCT03553420). Registered 14 March 2018, retrospectively registered.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-1295-y","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T16:05:34Z","timestamp":1579104334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["European lipodystrophy registry: background and structure"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-664X","authenticated-orcid":false,"given":"Julia","family":"von Schnurbein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ceccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"D\u2019Apice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gambineri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul C. M.","family":"Hennekam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Jeru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"Miehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermelinda","family":"Santos Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sbraccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Sorkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tanteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Vatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and Management of Lipodystrophy Syndromes: a Multi-society practice guideline. J Clin Endocrinol Metab. 2016;101:12.","journal-title":"J Clin Endocrinol Metab"},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:12.","journal-title":"N Engl J Med"},{"key":"1295_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40618-018-0887-z","volume":"42","author":"D Araujo-Vilar","year":"2019","unstructured":"Araujo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Investig. 2019;42:1.","journal-title":"J Endocrinol Investig"},{"key":"1295_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:11.","journal-title":"J Clin Endocrinol Metab"},{"key":"1295_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/DMSO.S130810","volume":"10","author":"E Chiquette","year":"2017","unstructured":"Chiquette E, Oral EA, Garg A, Araujo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375\u201383.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1295_CR6","first-page":"4","volume":"93","author":"CA Kim","year":"2008","unstructured":"Kim CA, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93:4.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1295_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/emmm.200900037","volume":"1","author":"O Rubio-Cabezas","year":"2009","unstructured":"Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):28.","journal-title":"EMBO Mol Med"},{"key":"1295_CR8","first-page":"1","volume":"84","author":"K Miehle","year":"2016","unstructured":"Miehle K, Porrmann J, Mitter D, Stumvoll M, Glaser C, Fasshauer M, et al. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3. Clin Endocrinol. 2016;84:1.","journal-title":"Clin Endocrinol"},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/jc.2006-1807","volume":"92","author":"H Monajemi","year":"2007","unstructured":"Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 2007;92:5.","journal-title":"J Clin Endocrinol Metab"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1210\/jc.2019-00849","volume":"104","author":"IVM J\u00e9ru","year":"2019","unstructured":"J\u00e9ru IVM, Bismuth E, Cervera P, Barraud S, PLIN1-Study Group, Auclair M, Vatier C, Lascols O, Savage DB, Vigouroux C. Diagnostic challenge in PLIN1-associated Familial Partial Lipodystrophy. J Clin Endocrinol Metab. 2019;104:12.","journal-title":"J Clin Endocrinol Metab"},{"key":"1295_CR11","unstructured":"European Consortium of Lipodystrophies. http:\/\/www.eclip-web.org. Accessed 1 July 2019."},{"key":"1295_CR12","volume-title":"Registries for evaluating patient outcomes: a user\u2019s guide","author":"AHRQ","year":"2014","unstructured":"AHRQ. Methods for effective health care. In: Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for evaluating patient outcomes: a user\u2019s guide. 3rd ed. Rockville: Agency for Healthcare Research and Quality (US); 2014.","edition":"3"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000444476","volume":"19","author":"A Coi","year":"2016","unstructured":"Coi A, Santoro M, Villaverde-Hueso A, Lipucci Di Paola M, Gainotti S, Taruscio D, et al. The quality of rare disease registries: evaluation and characterization. Public Health Genomics. 2016;19:2.","journal-title":"Public Health Genomics"},{"key":"1295_CR14","first-page":"209","volume":"253","author":"J Schaaf","year":"2018","unstructured":"Schaaf J, Kadioglu D, Goebel J, Behrendt CA, Roos M, van Enckevort D, et al. OSSE Goes FAIR - implementation of the FAIR data principles for an open-source registry for rare diseases. Stud Health Technol Inform. 2018;253:209\u201313.","journal-title":"Stud Health Technol Inform"},{"key":"1295_CR15","unstructured":"ECLip registry. http:\/\/134.60.15.143:8080\/login.xhtml. Accessed 1 July 2019."},{"key":"1295_CR16","unstructured":"Open Source Registry System for Rare Diseases in the EU (OSSE). https:\/\/www.osse-register.de\/en\/. Accessed 1 July 2019."},{"key":"1295_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12911-014-0123-5","volume":"15","author":"M Lablans","year":"2015","unstructured":"Lablans M, Borg A, Uckert F. A RESTful interface to pseudonymization services in modern web applications. BMC Med Inform Decis Mak. 2015;15:2.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1295_CR18","unstructured":"European Registries for Rare Endocrine Conditions (EuRRECa). https:\/\/eurreca.net\/. Accessed 1 July 2019."},{"key":"1295_CR19","unstructured":"EuRRECa expert working group on Rare Disorders Of Glucose & Insuline: https:\/\/eurreca.net\/ewg7-rare-disorders-of-glucose-insulin\/. Accessed 11 Oct 2019."},{"key":"1295_CR20","unstructured":"EUCERD core recommendations on rare disease patient registration and data collection. http:\/\/www.eucerd.eu\/wp-content\/uploads\/2013\/06\/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf. ."},{"key":"1295_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0166","volume":"180","author":"SR Ali","year":"2019","unstructured":"Ali SR, Bryce J, Cools M, Korbonits M, Beun JG, Taruscio D, et al. The current landscape of European registries for rare endocrine conditions. Eur J Endocrinol. 2019;180:1.","journal-title":"Eur J Endocrinol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-1295-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:30:16Z","timestamp":1610584216000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1295-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1295-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"8 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval has been obtained for 13 centres (the centres in Lille and Paris are in the process of obtaining approval):Ethics committee Ulm University, approval number 408\/17Ethics Committee of the University of Leipzig, approval number 029\/18-IkComit\u00e9 Auton\u00f3mico de \u00c9tica de la Investigaci\u00f3n de Galicia (Spain), approval number 2017\/477Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana Area Vasta Nord Ovest (CEAVNO), protocol number 4336 approved 21\/12\/2017Ethics committee Endocrinology Research Centre, Moscow, Russia, approval number 23 of December 27th, 2017Ethics committee Dokuz Eylul University, Turkey, IRB approval number 2018\/22\u201338Ethics committee \u201cArea Vasta Emilia Centro\u201d, S. Orsola-Malpighi hospital, university of Bologna, approval number 1302\/18Medical Ethics Committee Amsterdam University Medical Center, Amsterdam, approved 07\/07\/2017Ethics committee of the Policlinico Tor Vergata (Rome), approval number 214\/18Ethics committee of the \u00c4rztekammer Westfalen-Lippe und Westf\u00e4lischen Wilhelms-Universit\u00e4t, approval number 2018\u2013527-b-SCyprus National Bioethics Committee, approval number \u0395\u0395\u0392\u039a\/\u0395\u03a0\/2019\/40.Ethics committee- Wales REC 7, REC No. 19\/WA\/0095, Approved 1\/4\/19Ethics committee of the Centro Hospitalar Universit\u00e1rio do Porto (CHUP) and the Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar (ICBAS), Universidade do Porto, approval number 2019.081 (069-DEFI\/070-CE)Comit\u00e9 d\u2019expertise pour les recherches, les \u00e9tudes et les \u00e9valuations dans le domaine de la sant\u00e9 (CEREES): n\u00b0 INDS: TPS 33080bis, 06.09.2018","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The ECLip Registry does not receive any funding from private companies. Some of the authors have however received fees or funding from private companies for work unrelated to the ECLip Registry:J.v.S. has worked as a consultant for Rhythm Pharmaceuticals and Aegerion Pharmaceuticals and received travel funds from Ipsen, Novo Nordisk, and Merck Serono.D.A-V. has worked as an advisor for Bristol-Myers-Squibb, AstraZeneca, and Aegerion Pharmaceuticals.M.W. received personal fees from the Bristol-Myers Squibb, AstraZeneca and the Diabetes Alliance.C.Vi has has received personal fees for consultancy from AstraZeneca and Aegerion Pharmaceuticals, for lectures from Ipsen, Lilly, Viiv Healthcare, Janssen-Cilag, Boehringer-Ingelheim and Merck Serono, for travel from Aegerion Pharmaceuticals, Laboratoires Servier, Novo Nordisk, Orkyn, Sanofi, Vitalaire, Air Products, Boehringer-Ingelheim, Gilead, Novartis and Bristol-Myers Squibb, and has received institutional research fundings from Aegerion Pharmaceuticals, Pierre Fabre M\u00e9dicament, Laboratoires Servier and Roche Diagnostics.F. S has worked as a consultant, participated in studies and\/or received travel funds from the following companies that are involved with lipodistropy and\/or diabetes: AstraZeneca, Aegerion, Pharmaceuticals, Novo Nordisk, Bruno Pharma.M.C. V received non-financial support from Novartis, Aegerion Pharmaceuticials, Ipsen, Shire, HRA Pharma and personal fees from Sanofi.P. S. received fees as a consultant by Aegerion Pharmaceuticals, Novo Nordisk, Bruno Pharma and AstraZeneca.A. G. received fees as a consultant by Aegerion Pharmaceuticals.B.A. has attended Advisory Board Meetings organized by Aegerion Pharmaceuticals and Regeneron Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis.E.S.-S. has received a compensation from Aegerion Pharmaceuticals for her work as Consultant in a Portuguese Lipodystrophy Expert Meeting.E.S. has received fees for her work on an advisory board for Regeneron and for AstraZeneca.K.M. has received fees for consulting Aegerion Pharmaceuticals.G.C. has received fees for consulting AstraZeneca, Aegerion Pharmaceuticals and Rhythm Pharmaceuticals.C.Va. has has received personal fees for consultancy from AstraZeneca, Aegerion Pharmaceuticals, MSD, for lectures from Novo Nordisk, Sanofi, for travel from Aegerion Pharmaceuticals, Laboratoires Servier, Lilly, LVL, Novo Nordisk, Orkyn, Sanofi, Vitalaire, Novartis and has received institutional research fundings from Aegerion Pharmaceuticals, Sanofi.C.A. received honoraria as a speaker from Aegerion Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}